Categories Uncategorized

Earth Science Tech Inc. (ETST) Building on Synergies Between Healthcare Related Subsidiaries to Generate Dependable and Growing Revenue

  • Earth Science Tech operates several subsidiaries, including real estate and asset management company Avenvi LLC
  • Avenvi boasts expertise across various segments of the real estate industry, including identifying development opportunities and facilitating end-user property acquisitions
  • Avenvi also manages investments on behalf of ETST and provides the critical physical infrastructure for ETST’s expanding pharmacy operations

Earth Science Tech (OTCQB: ETST), a strategic holding company that brings together innovative businesses across the healthcare, pharmacy, technology and telemedicine, real estate, and consumer products spaces, operates Avenvi LLC, a real estate and asset management arm. Like its parent company, Avenvi is diversified, boasting expertise across various segments of the real estate industry and representing ETST’s diversification into hard assets.

Avenvi has developed a strong portfolio of real estate assets, primed for development, and provides financing solutions to purchasers of properties it develops. “This strategic positioning allows Avenvi to engage in the real estate market at every stage, from identifying development opportunities to facilitating end-user property acquisitions,” explains ETST in an SEC filing (https://ibn.fm/f9Fj4). As such, Avenvi serves as a distinct vehicle for hard-asset wealth generation.

Avenvi also manages investments on behalf of ETST, using a disciplined capital allocation approach focused on non-dilutive growth. It, for instance, manages Earth Science Tech’s share repurchase program, which management views as a long-term growth strategy. ETST began its common stock repurchase program on January 29, 2024, and had repurchased over 20.8 million shares of common stock by August 20, 2025 (https://ibn.fm/NVTxW), and over 6.9 million shares since April 1, 2025, through June 15, 2026 (https://ibn.fm/ODvn5).

“Extending and increasing this [common stock repurchase] program is a direct reflection of our confidence in ETST’s future and our unwavering commitment to our shareholders,” said Giorgio R. Saumat, CEO and Chairman of the Board.

The synergies between Avenvi and ETST also extend to the other subsidiaries under the ETST umbrella. Avenvi houses the standalone Mister Meds compounding pharmacy in Texas and provides the critical physical infrastructure for ETST’s expanding pharmacy operations. (ETST operates compounding pharmacies under the RxCompoundStore.com LLC, Mister Meds LLC, and Meduvo LLC brands.)

For more information, visit the company’s website at www.EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Blood Samples Could Be Used to Find Cancer-Specific Proteins Needed for Immunotherapy

Immunotherapy, a form of personalized cancer treatment, currently requires a tumor sample to be removed…

4 days ago

Regentis Biomaterials Is Addressing the ‘Short-Term Relief, Long-Term Failure’ Problem in Knee Cartilage Repair

One of the challenges in cartilage repair is that some procedures can provide meaningful short-term…

5 days ago

Health Insurance Has Spiked 78% in the US Since 2011

Surging health insurance costs have compelled even healthcare workers to stop getting coverage not only…

5 days ago

Nano-X Imaging CEO and Directors Report Open-Market Share Purchases

Nano-X Imaging Ltd. (NASDAQ: NNOX) today announced that recent SEC Form 4 filings disclosed open-market…

6 days ago

Earth Science Tech Inc. (ETST) Driving Sustainable Growth on New Technologies, In-House Expertise

Earth Science Tech is leveraging AI and other technology, along with the expertise of a…

1 week ago

Survey Shows Most American Adults Support Vaccination, But Uncertainty is Widespread

According to a new survey conducted by NFID (National Foundation for Infectious Diseases), the vast…

1 week ago